Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) had its price objective decreased by Stifel Nicolaus from $68.00 to $36.00 in a research note published on Thursday morning. Stifel Nicolaus currently has a hold rating on the biopharmaceutical company’s stock.

Other research analysts have also issued reports about the stock. Needham & Company LLC reissued a buy rating on shares of Alnylam Pharmaceuticals in a research note on Monday, June 13th. Credit Suisse Group AG reissued a buy rating on shares of Alnylam Pharmaceuticals in a research note on Sunday, June 12th. Cowen and Company reissued a buy rating on shares of Alnylam Pharmaceuticals in a research note on Sunday, June 12th. Leerink Swann reissued a buy rating on shares of Alnylam Pharmaceuticals in a research note on Sunday, June 12th. Finally, FBR & Co reissued a buy rating on shares of Alnylam Pharmaceuticals in a research note on Friday, June 10th. Eight research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The stock presently has a consensus rating of Buy and a consensus target price of $85.75.

Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) traded down 4.930% on Thursday, hitting $34.425. 2,990,331 shares of the stock were exchanged. The company’s market cap is $2.95 billion. The firm’s 50-day moving average is $71.81 and its 200-day moving average is $66.25. Alnylam Pharmaceuticals has a one year low of $34.18 and a one year high of $110.75.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.24) by $0.19. The firm earned $8.70 million during the quarter, compared to analyst estimates of $8.09 million. Alnylam Pharmaceuticals had a negative net margin of 1,204.91% and a negative return on equity of 29.60%. Alnylam Pharmaceuticals’s revenue was up .2% on a year-over-year basis. During the same period in the previous year, the business posted ($0.85) EPS. On average, equities analysts forecast that Alnylam Pharmaceuticals will post ($4.68) EPS for the current fiscal year.

In other Alnylam Pharmaceuticals news, CEO John Maraganore sold 30,151 shares of the company’s stock in a transaction that occurred on Wednesday, July 20th. The shares were sold at an average price of $64.69, for a total value of $1,950,468.19. Following the transaction, the chief executive officer now owns 148,465 shares in the company, valued at approximately $9,604,200.85. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 4.00% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Aperio Group LLC increased its stake in Alnylam Pharmaceuticals by 129.9% in the first quarter. Aperio Group LLC now owns 14,741 shares of the biopharmaceutical company’s stock valued at $925,000 after buying an additional 8,328 shares in the last quarter. Pacad Investment Ltd. acquired a new stake in Alnylam Pharmaceuticals during the first quarter valued at approximately $490,000. BlackRock Inc. increased its stake in Alnylam Pharmaceuticals by 29.7% in the first quarter. BlackRock Inc. now owns 69,736 shares of the biopharmaceutical company’s stock valued at $4,377,000 after buying an additional 15,965 shares in the last quarter. BlackRock Group LTD increased its stake in Alnylam Pharmaceuticals by 21.9% in the first quarter. BlackRock Group LTD now owns 519,834 shares of the biopharmaceutical company’s stock valued at $32,630,000 after buying an additional 93,450 shares in the last quarter. Finally, BlackRock Fund Advisors increased its stake in Alnylam Pharmaceuticals by 6.5% in the first quarter. BlackRock Fund Advisors now owns 1,838,376 shares of the biopharmaceutical company’s stock valued at $115,395,000 after buying an additional 112,252 shares in the last quarter. Hedge funds and other institutional investors own 85.96% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease.

5 Day Chart for NASDAQ:ALNY

Receive News & Stock Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.